Imperial College London
Portrait Picture

DrTonyTarragona-Fiol

Faculty of Medicine, Department of Surgery & Cancer

Divisional Manager
 
 
 
//

Contact

 

+44 (0)20 3312 7619t.tarragona

 
 
//

Location

 

1030Queen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@inproceedings{Jaoko:2008:10.1016/j.vaccine.2008.02.071,
author = {Jaoko, W and Nakwagala, FN and Anzala, O and Manyonyi, GO and Birungi, J and Nanvubya, A and Bashir, F and Bhatt, K and Ogutu, H and Wakasiaka, S and Matu, L and Waruingi, W and Odada, J and Oyaro, M and Indangasi, J and Ndinya-Achola, J and Konde, C and Mugisha, E and Fast, P and Schmidt, C and Gilmour, J and Tarragona, T and Smith, C and Barin, B and Dally, L and Johnson, B and Muluubya, A and Nielsen, L and Hayes, P and Boaz, M and Hughes, P and Hanke, T and McMichael, A and Bwayo, J and Kaleebu, P},
doi = {10.1016/j.vaccine.2008.02.071},
pages = {2788--2795},
title = {Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa},
url = {http://dx.doi.org/10.1016/j.vaccine.2008.02.071},
year = {2008}
}
Download

RIS format (EndNote, RefMan)

TY  - CPAPER
AB  - The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN-gamma) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. These trials demonstrated the feasibility of conducting high-quality Phase 1 trials in Africa.
AU  - Jaoko,W
AU  - Nakwagala,FN
AU  - Anzala,O
AU  - Manyonyi,GO
AU  - Birungi,J
AU  - Nanvubya,A
AU  - Bashir,F
AU  - Bhatt,K
AU  - Ogutu,H
AU  - Wakasiaka,S
AU  - Matu,L
AU  - Waruingi,W
AU  - Odada,J
AU  - Oyaro,M
AU  - Indangasi,J
AU  - Ndinya-Achola,J
AU  - Konde,C
AU  - Mugisha,E
AU  - Fast,P
AU  - Schmidt,C
AU  - Gilmour,J
AU  - Tarragona,T
AU  - Smith,C
AU  - Barin,B
AU  - Dally,L
AU  - Johnson,B
AU  - Muluubya,A
AU  - Nielsen,L
AU  - Hayes,P
AU  - Boaz,M
AU  - Hughes,P
AU  - Hanke,T
AU  - McMichael,A
AU  - Bwayo,J
AU  - Kaleebu,P
DO  - 10.1016/j.vaccine.2008.02.071
EP  - 2795
PY  - 2008///
SN  - 0264-410X
SP  - 2788
TI  - Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa
UR  - http://dx.doi.org/10.1016/j.vaccine.2008.02.071
UR  - http://www.ncbi.nlm.nih.gov/pubmed/18440674
UR  - internal-pdf://2777889352/Jaoko%202008%20Safety%20and%20immunogenicity%20of%20recomb.pdf
ER  -
Download